<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03976271</url>
  </required_header>
  <id_info>
    <org_study_id>HCIR</org_study_id>
    <nct_id>NCT03976271</nct_id>
  </id_info>
  <brief_title>Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses</brief_title>
  <acronym>HCIR</acronym>
  <official_title>Consequences of Hypoglycaemia on Cardiovascular and Inflammatory Responses in Patients With Diabetes Mellitus Type 1, Type 2 and Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Rigshospitalet, Denmark</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      People with Type 1 diabetes (T1DM), type 2 diabetes (T2DM) and healthy volunteers will&#xD;
      undergo a hypoglycaemic clamp to to investigate the effect of hypoglycaemia on cardiovascular&#xD;
      and inflammatory responses.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives: The overall aim of the present study is to investigate the effect of&#xD;
      hypoglycaemia on cardiovascular and inflammatory responses, molecular mechanisms and&#xD;
      epigenetic profiles in various groups of people with diabetes type 1, type 2 and healthy&#xD;
      volunteers.&#xD;
&#xD;
      Study design: Intervention study&#xD;
&#xD;
      Intervention: All subjects will undergo a hyperinsulinemic normoglycaemic-hypoglycaemic&#xD;
      glucose clamp (nadir 2.8 mmol/L), during and after which blood and urine will be sampled for&#xD;
      further examination for up to one week.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 12, 2019</start_date>
  <completion_date type="Actual">March 31, 2021</completion_date>
  <primary_completion_date type="Actual">March 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All subjects will undergo a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp (nadir 2.8 mmol/L), during and after which blood and urine will be sampled for further examination for up to one week.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Inflammatory responses of hypoglycaemia by measuring the cytokine production of isolated monocytes using ELISA</measure>
    <time_frame>1.5 year</time_frame>
    <description>Cytokine production (TNF-alfa, IL-6, IL-10 and IL-1β) of isolated and stimulated monocytes</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Atherogenic responses of (recurrent) hypoglycaemia using foam cell formation.</measure>
    <time_frame>1.5 year</time_frame>
    <description>Measurement of Ox-LDL uptake by measuring intracellular apolipoproteine B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolomics profile of each group</measure>
    <time_frame>1.5 year</time_frame>
    <description>Un-targeted metabolomics and identification of metabolites based on exact mass using metabolomics library</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epigenetic modifications</measure>
    <time_frame>1.5 year</time_frame>
    <description>Epigenetic modifications due to hypoglycaemia in the promoter regions of the pro-inflammatory cytokines in monocytes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac function responses to hypoglycaemia using echocardiography</measure>
    <time_frame>1.5 year</time_frame>
    <description>Cardiac function responses to hypoglycaemia using echocardiography</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cognitive function responses to hypoglycaemia using cognitive function tests (TAP, PASAT)</measure>
    <time_frame>1.5 year</time_frame>
    <description>Amount of correct answers</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxidative stress responses using oxidative stress marker</measure>
    <time_frame>1.5 year</time_frame>
    <description>Excretion of guanine nucleosides in urine (ng/mL)</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">110</enrollment>
  <condition>Hypoglycemia</condition>
  <condition>Inflammatory Response</condition>
  <condition>Diabetes Mellitus, Type 1</condition>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>T1DM poor glycaemic control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 1 diabetes and poor glycaemic control (HbA1c &gt;8% / &gt;64 mmol/mol will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM impaired awareness</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 1 diabetes and impaired awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T1DM Normal awareness</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 1 diabetes and normal awareness of hypoglycaemia will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>T2DM + Insulin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with type 2 diabetes with insulin treatment for at least 1 year will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control T2DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>healthy controls without diabetes and age, gender and BMI matched with diabetes type 2 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Healthy control T1DM</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Healthy controls without diabetes and age, gender and BMI matched with diabetes type 1 participants will undergo hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp</intervention_name>
    <description>For this study, a hyperinsulinemic normoglycaemic-hypoglycaemic glucose clamp will be conducted to investigate the effect of hypoglycaemia. This means that subjects will receive an intravenous insulin infusion, at a continuous rate of 60 mU∙m-2∙min-1, as well as glucose 20% w/w intravenously at a variable rate, adjusted by arterial plasma glucose levels, measured at 5 minute intervals.</description>
    <arm_group_label>Healthy control T1DM</arm_group_label>
    <arm_group_label>Healthy control T2DM</arm_group_label>
    <arm_group_label>T1DM Normal awareness</arm_group_label>
    <arm_group_label>T1DM impaired awareness</arm_group_label>
    <arm_group_label>T1DM poor glycaemic control</arm_group_label>
    <arm_group_label>T2DM + Insulin</arm_group_label>
    <other_name>hypoglycaemic clamp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Overall inclusion criteria&#xD;
&#xD;
          -  Ability to provide written informed consent&#xD;
&#xD;
          -  Must be able to speak and read Danish (for Hillerød-site) and Dutch (for&#xD;
             Nijmegen-site)&#xD;
&#xD;
          -  Insulin treatment according to basal-bolus insulin regimen (injections or insulin&#xD;
             pump) (except for group 5)&#xD;
&#xD;
          -  Body-Mass Index: 19-40 kg/m2&#xD;
&#xD;
          -  Age ≥18 years, ≤ 80 years&#xD;
&#xD;
          -  Blood pressure: &lt;140/90 mmHg&#xD;
&#xD;
          -  Duration of diabetes &gt; 1 year (except for group 5)&#xD;
&#xD;
          -  HbA1c &lt; 100 mmol/mol&#xD;
&#xD;
        Group specific&#xD;
&#xD;
          -  Group 1: HbA1c &gt;64 mmol/mol&#xD;
&#xD;
          -  Group 2: impaired awareness of hypoglycaemia (IAH) as assessed by a score of ≥3 on the&#xD;
             modified Clarke questionnaire, ≥4 on the Gold questionnaire and a positive score on&#xD;
             the Pedersen-Bjergaard questionnaire.&#xD;
&#xD;
          -  Group 3: normal awareness of hypoglycaemia (NAH) as assessed by a score of &lt;3 on the&#xD;
             modified Clarke questionnaire, &lt;4 on the Gold questionnaire and a negative score on&#xD;
             the Pedersen-Bjergaard.&#xD;
&#xD;
          -  Group 4: Insulin treatment for at least 1 year&#xD;
&#xD;
          -  Group 5/6: HbA1c &lt;42 mmol/mol&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  - Severe medical or psychological conditions interfering with the perception of&#xD;
             hypoglycaemia other than IAH such as brain injuries, epilepsy, a major cardiovascular&#xD;
             disease event or anxiety disorders&#xD;
&#xD;
          -  Use of immune-modifying drugs or antibiotics&#xD;
&#xD;
          -  Treatment with glucose-modifying (other than insulin, SGLT-2 inhibitors and metformin)&#xD;
             agents (e.g. prednisolon)&#xD;
&#xD;
          -  Use of anti-depressive drugs&#xD;
&#xD;
          -  Pregnancy or breastfeeding or unwillingness to undertake measures for birth control&#xD;
&#xD;
          -  Use of statins (e.g. stop statins &gt;2 weeks before performing blood sampling. This can&#xD;
             be safely done in the context of primary prevention)&#xD;
&#xD;
          -  Any event of cardiovascular disease in the past 5 years (e.g. myocardial infarction,&#xD;
             stroke, heart failure, symptomatic peripheral arterial disease)&#xD;
&#xD;
          -  Auto-inflammatory or auto-immune diseases&#xD;
&#xD;
          -  Any infection in past three months&#xD;
&#xD;
          -  Previous vaccination in the past three months&#xD;
&#xD;
          -  Laser coagulation for proliferative retinopathy in the past six months&#xD;
&#xD;
          -  Proliferative retinopathy&#xD;
&#xD;
          -  Diabetic nephropathy as reflected by an albumin-creatinine ratio ˃ 30 mg/gor an&#xD;
             estimated glomerular filtration rate (by MDRD) ˂60ml/min/1.73m2&#xD;
&#xD;
          -  History of pancreatitis (acute or chronic) or pancreatic cancer&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bastiaan E de Galan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ulrik Pedersen-Bjergaard, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nordsjællands University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nordsjællands University Hospital</name>
      <address>
        <city>Hillerød</city>
        <state>Nordsjaelland</state>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6525 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>November 8, 2018</study_first_submitted>
  <study_first_submitted_qc>June 3, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <last_update_submitted>May 11, 2021</last_update_submitted>
  <last_update_submitted_qc>May 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemic Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>No IPD sharing plan necessary</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

